Leads Biolabs Reports ESMO Data on Durable Responses
Leads Biolabs reported six ESMO 2026 abstracts. Its release said opamtistomig showed survival and response signals across cold tumors, while LBL-034 produced deep, sustained responses in RRMM with low rates of severe CRS. A late-breaking opamtistomig abstract is scheduled for presentation at ESMO.